Optimising low-dose methotrexate for rheumatoid arthritis-A review

Area of Science:

• Rheumatology
• Pharmacology
• Clinical Therapeutics

Background:

• Low-dose methotrexate (5-25 mg/week) is a primary treatment for rheumatoid arthritis.
• Significant inter- and intrapatient variability exists in treatment response.
• Variability in active methotrexate polyglutamate metabolite concentrations influences efficacy and toxicity.

Purpose of the Study:

• To review current knowledge on oral methotrexate dose-response in rheumatoid arthritis.
• To explore how dose-response data can inform optimized prescribing regimens.
• To address heterogeneous prescribing practices across diverse patient populations and disease states.

Main Methods:

• Literature review of existing studies on methotrexate dose-response.
• Analysis of factors contributing to variability in methotrexate metabolism and clinical outcomes.
• Synthesis of data to identify patterns in efficacy and toxicity related to dosage.

Main Results:

• Methotrexate response and toxicity are linked to polyglutamate metabolite levels.
• Current prescribing practices for methotrexate in rheumatoid arthritis are inconsistent.
• Evidence suggests a need for individualized dosing strategies based on patient-specific factors.

Conclusions:

• Optimizing methotrexate dosage regimens requires a deeper understanding of dose-response relationships.
• Individualized therapy, considering metabolic variability, may enhance clinical outcomes in rheumatoid arthritis.
• Further research into methotrexate pharmacokinetics and pharmacodynamics is warranted to refine treatment guidelines.